SEC Tracker
Get the app

Terns Pharmaceuticals

OrbiMed Genesis Master Fund (Director) plans to sell 152,400 shares, about $1.4M

Form
144
Filed
Importance
Routine
Document
Form 144
  1. Approximate sale date: Jul 15, 2024
  2. Broker: TD Cowen
  3. Shares acquired by: Private Placement

All of OrbiMed Genesis Master Fund's insider filings, holdings and planned sales

Form 4s that likely executed this notice (SEC Tracker's match by person, company, dates and shares):

  • Sold 39,433 shares at $10 on Jul 15, 2024 · Form 4
  • Sold 5,401 shares at $10 on Jul 15, 2024 · Form 4
  • Sold 6,142 shares at $10 on Jul 15, 2024 · Form 4
  • Sold 4,009 shares at $10 on Jul 16, 2024 · Form 4
  • Sold 556 shares at $10 on Jul 16, 2024 · Form 4
  • Sold 623 shares at $10 on Jul 16, 2024 · Form 4

Written from the Form 144 on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Terns Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Prothena PRTA public float $327M, Jun 30, 2025
  2. Altimmune ALT public float $327M, Jun 30, 2025
  3. Aura Biosciences AURA public float $321M, Jun 30, 2025
  4. Usana Health Sciences USNA public float $328M, Jun 27, 2025
  5. Nektar Therapeutics NKTR public float $318M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.